Drug Database
RE

recombinant human growth hormone (Ansomone)

✓ Approved

Anhui Anke Biotechnology · GHR · 重组蛋白

什么是 recombinant human growth hormone?

recombinant human growth hormone 是一种重组蛋白,由Anhui Anke Biotechnology研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Ansomone
公司Anhui Anke Biotechnology
药物类别重组蛋白, 多肽类
分子靶点GHR
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

recombinant human growth hormone 作用于 1 个分子靶点:

GHRgrowth hormone receptor (GHBP, GHIP)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

recombinant human growth hormone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersGrowth hormone deficiency✓ Approved

相关研究文献

PubMedNPJ precision oncology2026-11-19

Low-level Aurora kinase A amplification: CDK4/6 inhibitor resistance biomarker in hormone receptor-positive metastatic breast cancer.

Wander Seth A SA, Eli Lisa D LD, Rizvi Ezgi Karaesmen EK, Patel Roosheel Sandeep RS et al.

In this large, real-world, translational research cohort of 708 patients in the Tempus database who had hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer with prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) exposure, low-level Aurora kinase A (AURKA) copy-number (CN) gain was common, occurring in 106/708 patients (15.0%). These low-amplification (LA) events impacted RNA expression: patient samples with wild-type AURKA CN had significantly lower median AURKA RNA expression levels than did those with LA or amplified AURKA. Further, LA AURKA CN predicted inferior outcomes on CDK4/6i for patients with HR+, HER2- metastatic breast cancer: real-world progression-free survival was 16.9 months for wild type and 9.3 months for LA AURKA CN (hazard ratio, 1.74; 95% confidence interval, 1.42-2.13; P = 0.0003). These novel results represent the first real-world validation of LA AURKA CN gain as a potential predictor of CDK4/6i resistance.

PMID 43052382
阅读全文 →
PubMedBMC microbiology2026-11-19

Secretory expression of mature recombinant elafin in Pichia pastoris and assessment of its in vitro antibacterial and antifungal effects.

Mokhtari Somayeh S, Lohrasbi-Nejad Azadeh A, Torkzadeh-Mahani Masoud M, Zolala Jafar J

Elafin is a small human host-defense peptide derived from trappin-2/pre-elafin, known for its antiprotease and anti-inflammatory functions. However, direct comparative evidence on the antimicrobial activity of mature recombinant elafin, particularly against fungal organisms, remains limited. This study aimed to produce secreted mature recombinant elafin in Pichia pastoris X-33 and comparatively assess its antimicrobial activity in vitro against Escherichia coli ATCC 25,922, Pseudomonas aeruginosa ATCC 15,442, Staphylococcus aureus ATCC 29,737, and Candida albicans ATCC 10,231 using agar well diffusion, viable-count assays, broth microdilution, and minimum bactericidal/minimum fungicidal concentration (MBC/MFC) determination. The elafin insert was cloned into pPICZαA, and positive P. pastoris transformants were confirmed by colony PCR. Elafin was secreted into the culture medium, and the 66 h post-induction supernatant was selected for purification based on SDS-PAGE detection of a low-molecular-weight band in the expected size range. Purification resulted in a low-molecular-weight His-tagged recombinant product with migration consistent with the expected size of the designed elafin construct. In agar well diffusion assays, recombinant elafin produced inhibition zones of 32, 28, 25, and 22 mm for E. coli, P. aeruginosa, C. albicans, and S. aureus, respectively. Viable-count assays showed concentration- and time-dependent but modest reductions in recoverable cells, with all reductions remaining below 1 log₁₀ and the greatest effect observed at 62 µg/mL after 6 h. The minimum inhibitory concentration (MIC) values were 31 µg/mL for E. coli, P. aeruginosa, and C. albicans, and 62 µg/mL for S. aureus. The MBC values were 62 µg/mL for E. coli and P. aeruginosa, 124 µg/mL for S. aureus, and the MFC for C. albicans was 62 µg/mL. This study demonstrates the secretory expression and purification of a low-molecular-weight His-tagged recombinant product consistent with the designed mature elafin construct in P. pastoris. The purified peptide exhibited measurable in vitro inhibitory activity under defined assay conditions, supporting further evaluation of recombinant elafin in broader microbial and physiological models.

PMID 43052731
阅读全文 →
PubMedBulletin of experimental biology and medicine2026-11-19

FGD1 Gene Mutation Affects the Regulation of Endocytosis.

Egorov M V MV, Mikhaleva L M LM, Ilyichev A V AV

The intracellular distribution of transferrin, a marker of endocytosis, was studied in cells expressing mutant faciogenital dysplasia-1 (FGD1) protein. Mutations in the FGD1 gene underlie Aarskog-Scott syndrome, a rare genetic disorder characterized by impaired skeletal growth, urogenital abnormalities, and mental retardation. The experiments were conducted using HeLa cells expressing a GFP-tagged recombinant mutant FGD1 protein (FGD1-AS). Impaired transferrin internalization was revealed, evidenced by delayed accumulation of transferrin in recycling endosomes and perinuclear space compared to control cells. These data suggest that the FGD1 protein plays an important role in regulation of endocytosis.

PMID 43052635
阅读全文 →
PubMedJournal of hematology & oncology2026-11-19

Antibody-drug conjugates in HR-positive, HER2-negative metastatic breast cancer: evolving clinical roles and translational directions.

Lin Shengbo S, Zeng Cheng C, Liu Xuan X, Bao Xinyue X et al.

Rapid advances in antibody-drug conjugates (ADCs) and an expanding clinical evidence base are reshaping treatment options for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). Randomized trials have demonstrated progression-free survival benefits over chemotherapy for individual ADCs in defined populations, including settings before and after metastatic chemotherapy. As additional ADCs become available and indications expand, attention is increasingly focused on whether individual agents can improve outcomes over endocrine-based regimens in selected endocrine-eligible patients and on which therapies beyond conventional chemotherapy may retain activity after ADC progression. Addressing these questions requires integration of clinical evidence with a mechanistic understanding of ADC activity and resistance. In this review, we summarize selected mechanisms of ADC action and critically examine the evolving clinical roles of individual agents across settings defined by prior therapy. We also discuss treatment strategies after ADC exposure and resistance mechanisms relevant to target and payload selection. Finally, we review exploratory studies of candidate biomarkers associated with clinical outcomes, ADC-based combinations, and next-generation designs, highlighting their biological rationale, emerging evidence, and priorities for further evaluation.

PMID 43053184
阅读全文 →
PubMedPlant, cell & environment2026-11-19

Environmental Regulation of Secondary Metabolite Biosynthesis in Plants: Molecular Mechanisms, Ecological Adaptations and Biotechnological Prospects.

Sharma Nisha N, Ahlawat Yogesh K YK, Ponselvakumari Murugesan Kasthuribai MK, Kathula Karthika Vishnu Priya KVP et al.

Plants consistently come across a wide range of environmental obstacles that influence their growth, development and survival. The synthesis of specialised metabolites plays a vital role in defence and stress tolerance by plants. Specialised metabolites have a very close connection with primary metabolism via common precursors, energy, reducing power and the partitioning of carbon and nitrogen. Environmental stresses will result in a reprogramming of such interlinked metabolic pathways, which may cause changes in the production and storage of specialised metabolites as a possible response for acclimation and defence of plants. But this is not always helpful for plants under certain conditions. Biotic stresses (pathogenic infections) and microbial associations promote complex signalling pathways that activate plant defence mechanisms. These challenges often induce the accumulation of phytoalexins, phenolic compounds and other bioactive antimicrobial compounds through the stimulation of transcription factors and defence responsive genes. Hormone based signalling mediators (salicylic acid and ethylene), play a significant role in regulating these responses and facilitating metabolic activities associated in biosynthesis of secondary metabolites (SMs). Abiotic stresses (drought, salinity, temperature, radiations and heavy metals) also significantly affect SM production by inducing oxidative stress and inhibit cellular stability, leading to the initiation of antioxidant protection mechanism and triggers improved biosynthesis of SMs. The management of these metabolic pathways is regulated by stress induced genes, transcription factors and signal transduction frameworks including reactive oxygen species and hormone signalling interactions. This review focuses on the mechanisms of regulatory pathways directing the synthesis of SMs in plants under different environmental stresses. Current developments in Omics and molecular technologies, transcriptomics and metabolomics have provided greater understanding into the multifaceted regulatory networks mediating SM synthesis in plants. Conceptual understanding of these regulatory processes is essential for developing plant resilience and increased production of valuable plant derived compounds for various industrial applications. Overall, the regulation biosynthesis of SMs reflects a fundamental adaptive strategy that promotes plants to cope with environmental stress while assisting to ecological interactions and human health promoting benefits.

PMID 43053540
阅读全文 →
PubMedPlant physiology2026-11-19

The miR164-NAC module differentially regulates drought and salt tolerance in creeping bentgrass.

Chen Xiaotong X, Zhang Wensong W, Chen Zhaohui Z, Watts Ryan R et al.

MicroRNA164 (miR164) has been implicated in boundary formation and stress regulation in model annual species such as Arabidopsis and rice. However, experimental functional and mechanistic studies of miR164 in perennial grasses remain limited, and its broader impact on plant growth and stress performance is unclear. Creeping bentgrass (Agrostis stolonifera L.) is a C3 cool-season perennial turfgrass of major environmental and economic importance. In this study, we generated miR164 overexpression and knockdown creeping bentgrass transgenic lines and profiled their physiology, anatomy, hormone composition, and transcriptomes. We show that miR164 remodels plant architecture and water use. MiR164 overexpression reduces structural rigidity but enhances drought resistance, whereas miR164 knockdown through target mimicry increases biomass and structural rigidity, enhances salt tolerance, but exacerbates drought sensitivity. Direct manipulation of one of the miR164 targets, AsNAC2, reveals a narrow dosage window for normal plant development, as AsNAC2 overexpression and knockdown both severely stunted growth, with the knockdown resulting in a complete developmental arrest. The dwarfism observed in the AsNAC2 overexpression lines required a low water consumption and conferred a superior plant performance under drought. In addition, salt tolerance consistently improved in the miR164 knockdown and the NAC overexpression lines, through the upregulation of a Na⁺/H⁺ antiporter (AsNHX1) by an NAC-dependent stress-regulating binding motif. These findings establish the miR164-NAC module as a potential dosage-sensitive regulatory module that couples morphology, hormones, and ion transport, highlighting its potential for precision tuning to produce perennial grasses with optimized growth and stress resilience.

PMID 43053685
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多recombinant human growth hormone